4527 ロート薬

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	343,725	41,118	12.0%	47,971	14.0%	34,247	10.0%	151.56	11.4%	5.6%	18.7%	10.5%
2025/03	4Q	308,625	38,939	12.6%	40,430	13.1%	31,006	10.0%	136.11	14.0%	-2.8%	-4.7%	0.2%
2024/03	4Q	270,840	40,048	14.8%	42,434	15.7%	30,936	11.4%	135.61	13.5%	17.9%	19.3%	17.3%
2023/03	4Q	238,664	33,959	14.2%	35,568	14.9%	26,377	11.1%	115.62	19.5%	15.7%	22.3%	25.5%
2022/03	4Q	199,646	29,349	14.7%	29,084	14.6%	21,018	10.5%	184.26	10.1%	27.7%	21.6%	25.5%
2021/03	4Q	181,287	22,990	12.7%	23,910	13.2%	16,743	9.2%	146.78	-3.7%	-0.4%	5.2%	8.7%
2020/03	4Q	188,327	23,085	12.3%	22,735	12.1%	15,410	8.2%	135.13	2.6%	10.9%	19.8%	57.3%
2019/03	4Q	183,582	20,812	11.3%	18,970	10.3%	9,799	5.3%	86.00	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	343,725	41,118	12.0%	47,971	14.0%	34,247	10.0%	151.56	11.4%	5.6%	18.7%	10.5%
2025/03	4Q	308,625	38,939	12.6%	40,430	13.1%	31,006	10.0%	136.11	14.0%	-2.8%	-4.7%	0.2%
2024/03	4Q	270,840	40,048	14.8%	42,434	15.7%	30,936	11.4%	135.61	13.5%	17.9%	19.3%	17.3%
2023/03	4Q	238,664	33,959	14.2%	35,568	14.9%	26,377	11.1%	115.62	19.5%	15.7%	22.3%	25.5%
2022/03	4Q	199,646	29,349	14.7%	29,084	14.6%	21,018	10.5%	184.26	10.1%	27.7%	21.6%	25.5%
2021/03	4Q	181,287	22,990	12.7%	23,910	13.2%	16,743	9.2%	146.78	-3.7%	-0.4%	5.2%	8.7%
2020/03	4Q	188,327	23,085	12.3%	22,735	12.1%	15,410	8.2%	135.13	2.6%	10.9%	19.8%	57.3%
2019/03	4Q	183,582	20,812	11.3%	18,970	10.3%	9,799	5.3%	86.00	-	-	-	-